Sandra Lee, DCIS, and What Early Breast Cancer Can Mean

What Sandra Lee said in 2015

In May 2015, the food and lifestyle host Sandra Lee, then 48, said publicly that she had been diagnosed with breast cancer in March of that year. TODAY reported the disclosure. The diagnosis was ductal carcinoma in situ, usually shortened to DCIS.

The cancer was found on a routine mammogram, and she then had a biopsy. She was also tested for changes in the BRCA1 and BRCA2 genes, and the results were negative. She chose a double mastectomy, telling PEOPLE, "I never want to go through this again," and said she planned to spread the word about early detection.

Those were her decisions to make, and nothing here evaluates them. What is worth unpacking is the diagnosis itself, because DCIS confuses almost everybody, including people who have it.

What "in situ" actually means

The breast is built from ducts, which carry milk, and lobules, which produce it. Both are lined with cells, and both sit inside a wall of tissue.

In DCIS, cells inside a milk duct have turned abnormal, but they have not broken through the duct wall into surrounding breast tissue. That is what "in situ" means: in place. Because the cells have not crossed the wall, they have had no route into the lymph system or the bloodstream.

That is the whole distinction. An invasive breast cancer has crossed. DCIS has not, yet.

The 59,080 cases of female DCIS expected in the United States in 2025 were estimated by the American Cancer Society, alongside its estimates for invasive breast cancer, and the National Cancer Institute repeats them. NCI calls stage 0 breast cancer noninvasive, and gives DCIS as the example.

One neighbor of DCIS causes confusion. Lobular carcinoma in situ, or LCIS, sounds like the same thing at a different address. It is not. NCI notes that LCIS has been removed from TNM staging and is considered a benign entity, a marker of higher future risk rather than a cancer.

Why a "stage 0" diagnosis is still treated

If DCIS has not spread, why treat it at all? Because some of it would eventually break through the duct wall, and no test can currently identify which cases those are.

NCI lists the accepted options for DCIS: lumpectomy with radiation therapy, mastectomy with or without radiation, and hormone therapy if biomarker testing suggests it may help. Hormone therapy here means drugs such as tamoxifen or an aromatase inhibitor, which only work when the cells carry estrogen or progesterone receptors.

Several genuinely different approaches are all standard. That is unusual in medicine, and it is why DCIS decisions take longer conversations than people expect.

The uncomfortable number

Any honest article about DCIS has to include this. NCI's screening guidance for clinicians estimates that between 20% and 50% of screen-detected cancers represent overdiagnosis, meaning disease found that would never have caused symptoms or harm in that person's lifetime.

That statistic exists because mammography is good at finding DCIS, and DCIS does not always progress. Nobody can yet tell in advance which lesion is dangerous and which is inert, so all of them are treated.

The other half of the ledger is also real. NCI reports that screening mammography reduces breast cancer deaths, with solid evidence in women aged 60 to 69 and fair evidence in women aged 50 to 59.

Knowing both figures is what makes a screening decision informed rather than automatic.

About the BRCA test

Lee disclosed that she was tested for BRCA1 and BRCA2 and was negative. That test answers a narrower question than most people assume.

NCI explains that BRCA1 and BRCA2 are genes producing proteins that help repair damaged DNA. A harmful change in either raises lifetime breast cancer risk to more than 60%, against roughly 13% in the general population. For ovarian cancer, NCI puts lifetime risk at about 39% to 58% with a BRCA1 change and 13% to 29% with BRCA2, against roughly 1.1% generally.

A negative result is not a guarantee. Most breast cancer is not caused by an inherited BRCA change. NCI advises that anyone concerned about inherited risk discuss it with a health care provider or a genetic counselor rather than reason it out alone.

When to get checked

DCIS usually produces no lump and no symptom at all. It is typically found on imaging, often as tiny calcium deposits called microcalcifications. That is why screening matters here specifically.

The U.S. Preventive Services Task Force recommends screening mammography every two years for women aged 40 to 74, a grade B recommendation issued April 30, 2024.

Between mammograms, NCI lists these changes as reasons to call a doctor:

• A lump, or a thick or firm area, in or near the breast or under the arm.
• A change in the size or shape of one breast.
• Nipple discharge that is not breast milk.
• A nipple that flattens, inverts, or changes direction.
• Skin on the breast, nipple, or areola that becomes scaly, swollen, red, or darker.
• Dimpling, puckering, or a rash on the breast.
• Swelling of the whole breast with no lump.

Two warnings sit alongside that list. NCI states that breast cancer does not usually cause pain, so painlessness proves nothing. And NCI says to follow up on a breast change even if your last mammogram was normal.

How a diagnosis is confirmed

NCI is blunt: a biopsy is the only sure way to diagnose breast cancer. A suspicious mammogram leads to more targeted views, often an ultrasound, and then tissue sampling. Options include fine-needle aspiration, core-needle biopsy, image-guided biopsy, and removal of part or all of a lump. The sample is then tested for estrogen and progesterone receptors and for HER2, and graded from 1 to 3.

What the numbers show, at the population level

These figures describe groups and predict nothing for an individual.

SEER, the federal cancer statistics program, lists 321,910 new female breast cancers in the United States for 2026 and 42,140 deaths, both of them American Cancer Society projections. Five-year relative survival across all stages is 91.9% for women diagnosed from 2016 to 2022. For breast cancer that is still localized at diagnosis, SEER records five-year relative survival of 100.0%, and about 64% of cases are found at that point.

DCIS sits earlier than any of those categories, before invasion has occurred at all. That is why the conversation about it is less about survival and more about how much treatment a non-invasive finding deserves.

Sources

• NCI: Breast Cancer Treatment (PDQ) — Health Professional Version
• NCI: Breast Cancer Screening (PDQ) — Health Professional Version
• NCI: Treatment of Breast Cancer by Stage
• NCI: Breast Cancer Stages
• NCI: Signs and Symptoms of Breast Cancer
• NCI: How Is Breast Cancer Diagnosed?
• NCI: BRCA Gene Changes — Cancer Risk and Genetic Testing Fact Sheet
• SEER Cancer Stat Facts: Female Breast Cancer
• USPSTF: Breast Cancer Screening, final recommendation, April 30, 2024
• TODAY: Sandra Lee reveals breast cancer diagnosis, opts for double mastectomy
• American Cancer Society: Cancer Facts & Statistics